RIGEL PHARMACEUTICALS INC Financial Ratios
RIGL / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
93.8%
Profit Margin
124.7%
Net Income / Revenue
Asset Turnover
0.57
Revenue / Total Assets
Equity Multiplier
1.31
Total Assets / Equity
Composite: 93.8% (reported: 93.8%)
Profitability
Liquidity
Current Ratio
2.42
Quick Ratio
2.30
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.57
Inventory Turnover
1.71
Days Sales Outstanding
64 days
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Earnings Quality
Accrual Ratio
+86.0%
+94.5pp YoY
Earnings include a notable portion of accrual components.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.